Description
MNPR-101-PCTA-177Lu is an experimental treatment being studied in clinical trials for certain solid tumors, including colorectal cancer. It is being investigated as part of a Phase 1a trial (NCT06617169) to determine the right dose and how patients tolerate it. This trial is enrolling patients who have already participated in an earlier imaging study (MNPR-101-D001). The treatment involves intravenous infusions given over 20 minutes on specific days. The trial uses a special design (TITE-BOIN) to carefully adjust the dose based on how patients respond and any side effects they experience. Patients will be monitored closely for safety and effectiveness, including imaging scans (SPECT and CT) and blood tests. The goal of this early-stage trial is primarily to assess safety and find the maximum tolerated dose.
Mechanism of Action
MNPR-101-PCTA-177Lu is a type of treatment that combines an antibody with a radioactive substance (Lutetium-177). The antibody part is designed to target specific proteins found on certain cancer cells. The radioactive substance delivers radiation directly to those targeted cancer cells, potentially damaging or killing them. The specific protein targeted by MNPR-101 is being investigated in clinical trials. The trial is evaluating the safety and potential effectiveness of this approach in patients with solid tumors.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.